{"id":"https://openalex.org/W4361264313","doi":"https://doi.org/10.1158/0008-5472.c.6496280","title":"Data from A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity","display_name":"Data from A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity","publication_year":2023,"publication_date":"2023-03-30","ids":{"openalex":"https://openalex.org/W4361264313","doi":"https://doi.org/10.1158/0008-5472.c.6496280"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.c.6496280","doi":"https://doi.org/10.1158/0008-5472.c.6496280","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.c.6496280","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/0008-5472.c.6496280","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046281810","display_name":"Joseph R. Garlich","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph R. Garlich","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111740527","display_name":"Pradip K.R De","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pradip De","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012509754","display_name":"Nandini Dey","orcid":"https://orcid.org/0000-0002-5533-8784","observed_orcids":["https://orcid.org/0000-0002-5533-8784"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nandini Dey","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086855070","display_name":"Jing Dong Su","orcid":"https://orcid.org/0000-0001-5389-734X","observed_orcids":["https://orcid.org/0000-0001-5389-734X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jing Dong Su","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058134724","display_name":"Xiaodong Peng","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaodong Peng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033149936","display_name":"Antoinette Miller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Antoinette Miller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102095257","display_name":"Ravoori Murali","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ravoori Murali","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020581776","display_name":"Yiling Lu","orcid":"https://orcid.org/0000-0002-3662-2106","observed_orcids":["https://orcid.org/0000-0002-3662-2106"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yiling Lu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005221518","display_name":"Gordon Brent Mills","orcid":"https://orcid.org/0000-0002-0144-9614","observed_orcids":["https://orcid.org/0000-0002-0144-9614"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gordon B. Mills","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067033760","display_name":"Vikas Kundra","orcid":"https://orcid.org/0000-0002-3262-4059","observed_orcids":["https://orcid.org/0000-0002-3262-4059"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vikas Kundra","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072559407","display_name":"H-K. Shu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H-K. Shu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025517379","display_name":"Qiong Peng","orcid":"https://orcid.org/0000-0002-8515-1136","observed_orcids":["https://orcid.org/0000-0002-8515-1136","https://orcid.org/0009-0001-3666-1359"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qiong Peng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5025976004","display_name":"Donald L. Durden","orcid":"https://orcid.org/0000-0001-5386-1427","observed_orcids":["https://orcid.org/0000-0001-5386-1427"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Donald L. Durden","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9868000149726868,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9868000149726868,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.005100000184029341,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ly294002","display_name":"LY294002","score":0.8489999771118164},{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.6489999890327454},{"id":"https://openalex.org/keywords/pan-pi3k-inhibitor","display_name":"pan-PI3K inhibitor","score":0.8640000224113464},{"id":"https://openalex.org/keywords/integrin-targeting","display_name":"integrin targeting","score":0.7860000133514404},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.7239999771118164},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8460000157356262},{"id":"https://openalex.org/keywords/pten","display_name":"PTEN","score":0.6930000185966492},{"id":"https://openalex.org/keywords/akt-phosphorylation","display_name":"Akt phosphorylation","score":0.9750000238418579},{"id":"https://openalex.org/keywords/tumor-vasculature-targeting","display_name":"tumor vasculature targeting","score":0.7990000247955322},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.734000027179718}],"concepts":[{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.847123920917511},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6631823182106018},{"id":"https://openalex.org/C2776912716","wikidata":"https://www.wikidata.org/wiki/Q4042503","display_name":"LY294002","level":4,"score":0.6400296688079834},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.6143178343772888},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5841382145881653},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5519199967384338},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.5367212891578674},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5148288607597351},{"id":"https://openalex.org/C2781322055","wikidata":"https://www.wikidata.org/wiki/Q423725","display_name":"Phosphoinositide 3-kinase","level":4,"score":0.4935063123703003},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.48352599143981934},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2889878749847412},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.24360817670822144},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.21533527970314026},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.15825995802879333},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/0008-5472.c.6496280","doi":"https://doi.org/10.1158/0008-5472.c.6496280","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.c.6496280","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.c.6496280","doi":"https://doi.org/10.1158/0008-5472.c.6496280","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.c.6496280","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2005448885","https://openalex.org/W2506878738","https://openalex.org/W2241003473","https://openalex.org/W4241124341","https://openalex.org/W3019256966","https://openalex.org/W2589141964","https://openalex.org/W1999504067","https://openalex.org/W2023041438","https://openalex.org/W2107343029","https://openalex.org/W4361813025"],"abstract_inverted_index":{"Abstract":[0],"PTEN":[1],"and":[2,17,38,46,64,85,94,108,146,162,182],"the":[3,44,70,78,82,115,138,147,189,197],"pan":[4,172,192],"phosphoinositide":[5],"3-kinase":[6],"(PI3K)":[7],"inhibitor":[8,174],"2-(4-morpholinyl)-8-phenyl-4H-1benzopyran-4-one":[9],"(LY294002)":[10],"exert":[11],"significant":[12],"control":[13],"over":[14],"tumor-induced":[15],"angiogenesis":[16],"tumor":[18,71,83,110,144],"growth":[19,111],"in":[20,74,98,143,153,180],"vivo.":[21,154],"The":[22,101,165],"LY294002":[23,53],"compound":[24,80],"is":[25,58,88,95],"not":[26],"a":[27,50,126,170,186],"viable":[28,171],"drug":[29],"candidate":[30],"due":[31],"to":[32,60,66,81,105,158],"poor":[33],"pharmacologic":[34],"variables":[35],"of":[36,49,77,103,133,141,150,191,199],"insolubility":[37],"short":[39],"half-life.":[40],"Herein,":[41],"we":[42],"describe":[43],"development":[45],"antitumor":[47,161],"activity":[48,123,132],"novel":[51],"RGDS-conjugated":[52],"prodrug,":[54,129],"termed":[55],"SF1126,":[56],"which":[57],"designed":[59],"exhibit":[61,159],"increased":[62,122],"solubility":[63],"bind":[65],"specific":[67],"integrins":[68],"within":[69],"compartment,":[72],"resulting":[73],"enhanced":[75,113],"delivery":[76],"active":[79],"vasculature":[84],"tumor.":[86],"SF1126":[87,104,134,142,156,168],"water":[89],"soluble,":[90],"has":[91],"favorable":[92],"pharmacokinetics,":[93],"well":[96],"tolerated":[97],"murine":[99],"systems.":[100],"capacity":[102],"inhibit":[106],"U87MG":[107],"PC3":[109],"was":[112,135],"by":[114],"RGDS":[116],"integrin":[117],"(\u03b1v\u03b23/\u03b15\u03b21)":[118],"binding":[119],"component,":[120],"exhibiting":[121],"compared":[124],"with":[125,137],"false":[127],"RADS-targeted":[128],"SF1326.":[130],"Antitumor":[131],"associated":[136],"pharmacokinetic":[139],"accumulation":[140],"tissue":[145],"pharmacodynamic":[148],"knockdown":[149],"phosphorylated":[151],"AKT":[152],"Furthermore,":[155],"seems":[157],"both":[160],"antiangiogenic":[163],"activity.":[164],"results":[166],"support":[167,184],"as":[169],"PI3K":[173,193],"for":[175,185,196],"phase":[176],"I":[177],"clinical":[178],"trials":[179],"cancer":[181],"provide":[183],"new":[187],"paradigm,":[188],"application":[190],"inhibitory":[194],"prodrugs":[195],"treatment":[198],"cancer.":[200],"[Cancer":[201],"Res":[202],"2008;68(1):206\u201315]":[203]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2023-03-31T00:00:00"}